Matthew Winter, Rob Coleman, Jessica Kendall, Carlo Palmieri, Chris Twelves, Sacha Howell, Iain MacPherson, Caroline Wilson, Kash Purohit, Jacqui Gath, Christine Taylor, Richard Eastell, Geraldine Murden, Sarah R Brown, Emma Rathbone, Janet Brown
BACKGROUND: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidity, there remains an unmet need for further treatment options. Radium-223 (Ra223 ) is an alpha-emitting radiopharmaceutical that is preferentially taken up into bone at sites of increased osteoblastic activity where it emits high-energy, short-range alpha-particles that could provide a targeted anti-tumour effect on bone metastases...
August 2022: Journal of Bone Oncology